Last reviewed · How we verify
Furmonertinib 240mg
Furmonertinib 240mg is a Small molecule drug developed by Allist Pharmaceuticals, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | Furmonertinib 240mg |
|---|---|
| Sponsor | Allist Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases (PHASE3)
- High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI (PHASE2)
- Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation (PHASE1)
- Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion (PHASE2)
- Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation (PHASE1)
- High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Furmonertinib 240mg CI brief — competitive landscape report
- Furmonertinib 240mg updates RSS · CI watch RSS
- Allist Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about Furmonertinib 240mg
What is Furmonertinib 240mg?
Furmonertinib 240mg is a Small molecule drug developed by Allist Pharmaceuticals, Inc..
Who makes Furmonertinib 240mg?
Furmonertinib 240mg is developed by Allist Pharmaceuticals, Inc. (see full Allist Pharmaceuticals, Inc. pipeline at /company/allist-pharmaceuticals-inc).
What development phase is Furmonertinib 240mg in?
Furmonertinib 240mg is in Phase 1.
Related
- Manufacturer: Allist Pharmaceuticals, Inc. — full pipeline
- Compare: Furmonertinib 240mg vs similar drugs
- Pricing: Furmonertinib 240mg cost, discount & access